Table 3.

Self-reported Adverse Reactions, Breath-holding Failures, and Image Artifacts in Age- and Sex-matched Patient Pairs

	Site A, Unmatched			Site A, Matched
Parameter	Gadoxetic Acid (n = 146)	Gadobenate Dimeglumine (n = 226)	P Value	Gadoxetic Acid (n = 130)	Gadobenate Dimeglumine (n = 130)	P Value	Site B: Gadoxetic Acid (n = 130)
Self-report of adverse effect	14 (9.6)	8 (3.5)	.017	10 (7.7)	6 (4.6)	.300	4 (3.1)
Nausea	2 (1.4)	5 (2.2)	.709	2 (1.5)	4 (3.1)	.684	0
Vomiting	0	0	…	0	0	…	0
Allergy like	0	0	…	0	0	…	0
Dyspnea	10 (6.9)	0	<.001	8 (6.2)	0	.007	2 (1.5)
Other	2 (1.4)	3 (1.3)	.999	0	2 (1.5)	.498	2 (1.5)
Substantial decrease in Spo2
Precontrast	5 (3.4)	16 (7.1)	.101	5 (3.9)	12 (9.2)	.130	2 (1.5)
Arterial phase	12 (8.2)	20 (8.9)	.853	11 (8.5)	14 (10.9)	.514	3 (2.3)
Only arterial phase	10 (6.9)	12 (5.3)	.542	9 (6.9)	8 (6.2)	.802	3 (2.3)
Breath-holding failure
Precontrast	18 (12.3)	16 (7.1)	.093	14 (10.8)	9 (7.0)	.282	1 (0.8)
Arterial phase	52 (35.6)	24 (10.7)	<.001	45 (34.6)	15 (11.7)	<.001	21 (16.2)
Only arterial phase	40 (27.4)	10 (4.4)	<.001	36 (27.7)	8 (6.2)	<.001	20 (15.4)
Substantial image artifacts
Precontrast	1 (0.7)	4 (1.8)	.919	1 (0.8)	3 (2.3)	.622	4 (3.1)
Arterial phase	33 (22.6)	7 (3.1)	<.001	29 (22.3)	4 (3.1)	<.001	20 (15.4)
Only arterial phase	32 (21.9)	7 (3.1)	<.001	28 (21.5)	4 (3.1)	<.001	17 (13.1)
Severe image artifacts
Precontrast	0	0	…	0	0	…	0
Arterial phase	11 (7.5)	1 (0.4)	<.001	10 (7.7)	0	<.001	3 (2.3)
Only arterial phase	11 (7.5)	1 (0.4)	<.001	10 (7.7)	0	<.001	3 (2.3)

Note.—Data are numbers of patients, with percentages in parentheses.